Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This randomized, controlled, single center clinical trial aims to evaluate the efficacy and
safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer
with a six-month treatment cycle.